Compare IVDA & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVDA | VIVS |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 2.5M |
| IPO Year | 2015 | 2010 |
| Metric | IVDA | VIVS |
|---|---|---|
| Price | $0.34 | $0.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.9M | 5.9M |
| Earning Date | 05-12-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,468,279.00 | ★ $4,603,000.00 |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.98 | 8.82 |
| 52 Week Low | $0.21 | $0.26 |
| 52 Week High | $2.24 | $5.30 |
| Indicator | IVDA | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 28.62 |
| Support Level | $0.24 | N/A |
| Resistance Level | $0.42 | $0.58 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 24.67 | 6.20 |
Iveda Solutions Inc offers smart city technologies globally, offering AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products). Geographically, the company operates in USA and Taiwan, majority of its revenue is generated from Taiwan.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.